Penn Medicine developing next generation of viral vectors for genome editing
In May, Penn announced a gene therapy alliance with Biogen, the oldest biotechnology company in the United States, aimed at advancing gene therapy research and gene editing technologies. The collaboration, potentially worth up to $2 billion for the ...
For more information, please visit
Feed last updated 2020/08/31 @3:08 AM